logo
Grand Sierra Resort quietly seeks public financing, legislative help for basketball arena

Grand Sierra Resort quietly seeks public financing, legislative help for basketball arena

When Alex Meruelo unveiled plans for a $1 billion expansion to his Grand Sierra Resort in Reno 18 months ago — including a $400 million state-of-the-art sports arena to house the Nevada men's basketball team — there was barely a mention of the financing.
Meruelo compared his planned venue to the privately financed, $375 million T-Mobile Arena in Las Vegas and said the school was off the hook.
'One thing that I made sure that I said over and over again — this arena will not cost the university one dollar,' Meruelo said at the September 2023 announcement inside a Grand Sierra Resort night club that was attended by cheerleaders, Wolf Pack mascots, school President Brian Sandoval and Reno Mayor Hillary Schieve.
Nobody asked whether Meruelo would seek public financing. A year later, it's clear the answer is 'yes.'
Grand Sierra is seeking $97 million in public money from the City of Reno through tax increment financing (TIF). The financing could raise close to 10 percent of the overall arena costs and fund other development elements, including a new hotel tower and non-gaming enhancements such as a Top Golf-style driving range surrounding the existing resort.
TIFs are a public funding mechanism that work by freezing property taxes in a given area, and then diverting property tax revenue generated from a new project back to the developer to pay for the construction costs. Proponents of TIF projects say they help reduce blight and fund infrastructure investments in areas that otherwise wouldn't be developed, but opponents say their structure can be overly opaque and keep tax dollars away from municipal governments, which still have to provide services to the region.
Simultaneously, state lawmakers are considering legislation that would benefit the project by extending the timeline of TIF funding for the city's redevelopment plans. Lawmakers and project proponents have noted that no public funding will come from the state, which is facing financial headwinds as the federal government weighs possible funding cuts.
But the plan is being opposed by a coalition of competing resort operators who don't believe TIF money should be used. The group, which includes owners of the Eldorado and Silver Legacy, Sparks Nugget and Peppermill, said the TIF funds are normally targeted at blighted areas to provide economic growth.
'(Grand Sierra Resort) is clearly willing and able to pay the up-front construction costs,' Joshua Hicks, an attorney from McDonald Carano that is representing the group, wrote in a letter to the Reno City Council on March 11. 'It seems clear that the (Grand Sierra) intends to use TIF not for construction costs, but instead to offset ongoing operational costs. We do not believe this is an appropriate use of TIF under Nevada law.'
In a statement provided to The Nevada Independent on Friday, Meruelo said his company has 'put forward a proposal that places all of the risk on the (Grand Sierra), which is why it's surprising the other local gaming operators are opposing this transformational development.'
Meruelo said downtown Reno 'has enjoyed the benefits of TIF funded projects for the past 30 years,' including the 9,100-seat Greater Nevada Field, home to the Triple-A Reno Aces, and the National Bowling Stadium.
'While these facilities have provided substantial direct benefits to the downtown casinos, they have also burdened the City of Reno with large debts,' Meruelo said.
In an interview Wednesday, Schieve said the initial discussions with Meruelo's group took place before the September 2023 announcement and the plans were 'very vague,' but her impression was that 'they were looking at certain economic development tools.'
The mayor said she is requesting Grand Sierra representatives and the university make a full presentation to the city council on April 9 'on exactly what the project is. That needs to happen before we can move forward.'
Developers said in October that the arena's construction was contingent on the Grand Sierra qualifying for the financing and would reduce future property taxes by $89.7 million.
Andrew Diss, senior vice president for Meruelo Gaming, which operates the Grand Sierra and the Sahara Hotel and Casino in Las Vegas, questioned why there is opposition.
'We can't figure it out. In Vegas, there is a mentality that something built near the Strip, whether it's Allegiant Stadium or the Sphere, benefits everybody,' Diss said in an interview last week. 'We're building a 10,000-seat arena, and we only have 2,000 rooms at (Grand Sierra). So people coming in for concerts or anything else are going to be staying at all these other properties.'
Diss said seeking public financing assistance had always been an option, especially for the arena component, which includes a public ice skating facility and a large parking structure.
Hicks, speaking on behalf of the coalition, said in an email the properties were initially supportive of the arena plans but felt obligated to speak against it when they learned the extent of the public financing request.
'We feel strongly that redevelopment funds should be reserved for blighted areas in need of public assistance and should not be committed to areas that are already developed,' Hicks wrote.
TIFs in Reno
Use of TIF funding structures is common in Reno — projects funded through the public financing system have helped fund development of the baseball and bowling stadiums, the city's Locomotion Plaza in 2021 and the 7,000-seat Reno Events Center, which opened in 2005.
Meanwhile, to address the funding mechanism's expiration in 2035, Sen. Edgar Flores (D-Las Vegas) is sponsoring SB401 on behalf of Meruelo Gaming. The redevelopment district that includes Grand Sierra was established in 2005, and under Nevada law, redevelopment district plans terminate after 30 years.
The bill would extend the termination timeline for redevelopment plans affecting blighted areas from 30 to 50 years in the city of Reno.
Flores said he probably wouldn't need to propose the law if the pandemic hadn't happened, leading to a slowdown in construction and longer development timelines, and the Grand Sierra Resort wasn't the only entity that reached out to him about extending the timeline.
He stressed that the bill does not intend to provide state funds for the project.
'We just want to look at what was out there now and allow them to utilize the full breadth of its timeline,' he said.
Though financial records show Flores received $3,500 from gaming industries, Meruelo did not donate to the senator.
Schieve, who could eventually vote on the TIF issue as a Reno City Council member, said she hasn't seen the bill from Flores and the devil is in the details. But she believes she could support expanding the redevelopment period because developers lost a lot of time with the COVID-19 pandemic and housing shortage.
Diss said extending the lifespan of TIF helps build projects such as Grand Sierra in phases. In addition to the arena, parking structure and ice skating venue, plans call for a new hotel tower to expand the nearly 2,000-room resort, condos for staff, a walkable promenade, driving range, fountain show and dining venues near the lake at the south entrance of the 150-acre property.
'You have to build a project like this in phases, and let's face it — tariffs are in place and structural changes, such as the cost of steel for the arena, have gone up 25 percent,' Diss said. 'In 10 years, we could be north of a billion dollars.'
Schieve said she wants to ensure the project benefits the city and sparks economic development and tourism.
'TIF is one of our tools (and) we're certainly looking at (it),' she said. 'We need to stay competitive.'
Diss said the bill 'needs to be approved in the next few weeks' because of the arena's construction timeline. Developers want the venue to be ready in fall 2027 for the start of the basketball season.
Public financing in other venue projects
The request by Grand Sierra Resorts isn't the first time public financing has been used on sports venues in Nevada.
Public financing — about one-third of which was covered by Washoe County's car rental tax — helped build Greater Nevada Field in Reno. The managing partners of SK Baseball were Manhattan Capital Sports Fund executives Stuart Katzoff and Jerry Katzoff, but real estate developer Herb Simon put in $50 million in private money.
Although Howard Hughes Corp. privately financed the $150 million Las Vegas Ballpark in Downtown Summerlin that houses the Las Vegas Aviators, the Las Vegas Convention and Visitors Authority helped with an $80 million naming rights agreement. The LVCVA is funded by hotel room taxes paid by visitors to Strip and downtown casinos.
Two large stadiums in Las Vegas — the $1.9 billion Allegiant Stadium and a planned $1.75 billion baseball park — were the subject of public funding bills during two legislative special sessions.
Allegiant received $750 million in public financing during a 2016 special legislative session.
In 2023, Major League Baseball's then-Oakland Athletics won approval from state lawmakers for a $380 million public financing package.
Striking out in Phoenix
This isn't the first time Meruelo has faced pushback on an arena he's tried to build.
A few years ago, Meruelo failed to construct a hockey arena in Phoenix for the NHL's Arizona Coyotes, which he bought in 2019 for $300 million.
In 2023, residents of Tempe, a Phoenix suburb, rejected a $2.1 billion entertainment district that would have included a 16,000-seat hockey arena. Meruelo sought other locations, including a portion of a 100-acre site in Scottsdale that was ultimately rejected by the city.
The Coyotes played two seasons in the 4,600-seat Mullett Arena at Arizona State University before the NHL ordered the franchise sold in 2024 to a Utah group for $1.2 billion. The group moved the team to Salt Lake City.
Meruelo is suing the Arizona Board of Regents to recover a $3.5 million security deposit paid to the school for use of the arena, saying the 'forced sale' of the team excused the franchise from the final year of its lease agreement.
Challenging financial times
The financing request comes amid unprecedented uncertainty about the state's budget status and as the City of Reno faces a $3.7 million shortfall in its $862 million annual budget.
Alongside the financial uncertainty, Northern Nevada casino operators told the Reno City Council in the letter that it should not award any TIF funds to the Grand Sierra because using the financing mechanism for hotel-casino 'does not appear to be lawful' — it is designed to revitalize blighted areas that would otherwise remain stagnant.
'As many of these parcels are well-kept and only serve the resort and guests, there is little need for redevelopment in this area and thus little need for redevelopment funding support,' Hicks wrote.
Diss said Grand Sierra began seeking TIF funding because the property is in an area of Reno designated as a redevelopment district.
'We weren't sure if we could do it all on our own,' Diss said. 'Nothing is getting cheaper. To do projects at this scale, (utilizing public financing) is the only way it pencils out that it will be successful.'
He said the public financing would generate returns for the city — a theory supported by a Reno city government staff report.
'The city wants the arena built first because of the sales tax generation it will create,' Diss said.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Say goodbye to style over comfort — these Canadian-made jeans are ticking all the boxes!
Say goodbye to style over comfort — these Canadian-made jeans are ticking all the boxes!

Yahoo

time2 hours ago

  • Yahoo

Say goodbye to style over comfort — these Canadian-made jeans are ticking all the boxes!

As anyone who's hunted for the perfect pair of jeans knows, it's rare to find denim that hits that sweet spot between comfort and structure. Too stretchy, and they lose shape. Too stiff, and you're counting down the minutes until you can change. Enter: DUER's Performance Denim Mid Rise Slim Straight Jeans, the Canadian denim that your closet has been waiting for. With rave reviews and thoughtful design details, these jeans are quickly becoming a go-to choice for shoppers seeking a stylish staple that's versatile and made for real life. Based in Vancouver, DUER is known for its innovative fabrics and elevated staples made for 'doers' (get it?), a.k.a, people who don't want to choose between style and performance. Because we really can have it all! Pictured here in Dark Stone. The Slim Straight style features a mid-rise waist, a flattering slim fit through the hip and thigh, and a slightly looser leg opening for a straight, classic finish. Translation? They look good with everything from sneakers to heels and have a timeless, easy-to-style silhouette that won't feel dated after one season. But what really sets these jeans apart is how they feel. They're breathable, soft to the touch, and move with you, making them a favourite for travel, long days out, or anyone who simply doesn't want to sacrifice comfort for style. Designed with everyday movement in mind, these jeans are made using the brand's signature stretch fabric, which includes natural fibres like cotton, eucalyptus-derived tencel and a touch of spandex for just the right amount of give. 👖 600+ reviews ⭐ 4.8/5 stars 🏅 "The perfect addition to my wardrobe!" With a near-perfect 4.7-star rating from hundreds of reviews, these jeans have clearly struck a chord with denim lovers across Canada. 'These jeans are so comfortable! I wore them on a long-haul flight and was amazed at how well they held up. No sagging, no stiffness, just the perfect fit,' one reviewer shared. Pictured here in Aged Medium Stone, these jeans are available in four additional colourways. Another echoed the sentiment: 'They fit like a glove, have great stretch without losing their shape, and feel like they were made for movement. I've worn them to the office and out to dinner.' That said, not every review is glowing, but we appreciate honest feedback. One shopper noted that while the material felt high-quality, the sizing didn't quite work for them: "I really wanted to love these jeans, but I found the waist too snug compared to the fit in the legs. I had to size up, which made the rest of the jeans looser than I'd like. Might just not be the right cut for my shape.' While this might be a matter of personal fit, it's a good reminder to check DUER's size guide and reviews before ordering, especially if you're between sizes. It's safe to say that DUER's Slim Straight Jeans in Aged Medium Stone are worth the hype, with the local Canadian aspect, as well as ethical production and stellar reviews. And at a moderate price-point, they're an investment that pays off every time you reach for them (which will be often). Available in several washes and fits to suit your personal style, these are jeans you'll want to live in, and according to hundreds of happy shoppers, you absolutely can. These jeans are the perfect blend of effortless cool, all-day comfort and vintage vibes. These trousers are where tailored elegance meets everyday comfort, making them your go-to for effortlessly chic style. Perfect for any summer activity, this laid-back yet elevated jumpsuit is about to become your new BFF. With a flattering high rise and laid-back wide leg, these jeans bring retro-cool energy and all-day comfort to every outfit. No matter where you stand on the skinny jean trend, this high waisted pair are a great option. A more comfortable pair of jeans doesn't exi—

Michelle Obama couldn't be more wrong about women Trump voters
Michelle Obama couldn't be more wrong about women Trump voters

New York Post

time5 hours ago

  • New York Post

Michelle Obama couldn't be more wrong about women Trump voters

I'm a pro-choice feminist — and a Democrat — who just happened to vote for Donald Trump for president. And I resent Michelle Obama's sneering, demeaning, strangely ignorant and massively sexist remarks about women, our reproductive systems and, especially, our vote. In the latest episode of the podcast, 'IMO with Michelle Obama & Craig Robinson,'' the former first lady and lefty pro-abortion activist mounted her high horse and disgracefully disparaged a woman's decision to exercise her right to choose what to do with her body. That is, when that choice is to have a baby. On the podcast she shares with her celebricat brother, the 61-year-old mother of two daughters, insanely breathed strength into the pro-life crowd by declaring bizarrely that creating life is 'the least' of what a woman's reproductive system does. Advertisement 'I attempted to make the argument on the campaign trail this past election was that there's just so much more at stake and because so many men have no idea about what women go through,' Obama said, delving treacherously close to Democratic-style word salad. 'Women's reproductive health is about our life. It's about this whole complicated reproductive system that the least of what it does is produce life.' When does a reproductive system have nothing to do with reproduction? Willful ignorance Mrs. O showed stupendously willful ignorance about her fellow ladies' inner workings. Advertisement 'It's a very important thing that it does, but you only produce life if the machine that's producing it — if you want to whittle us down to a machine — is functioning in a healthy, streamlined kind of way,' Obama added. I guess she missed that day in biology class. Speaking with OB/GYN Dr. Sharon Malone, whose husband, Eric Holder, served as attorney general under former President Barack Obama, Michelle then took aim at the male of the species. Advertisement She attacked guys who, she said, 'sit on their hands' over abortion and are choosing to 'trade out women's health for a tax break or whatever it is.'' But the crescendo came when she denounced women like me of handing the election to President Trump because — get this — we were too stupid or timid to vote for the worst candidate ever to grace a ballot, simply because she is female. In Obama's world, we voted for Trump to please men. Seriously? Advertisement 'There are a lot of men who have big chairs at their tables, there are a lot of women who vote the way their man is going to vote,'' she actually said. 'It happened in this election.' So there it is. Michelle Obama, pretend women's rights warrior, is so condescending to the fairer sex, she insults millions of people bearing XX chromosomes by claiming they were merely trying to please 'their'' man by going for Trump. Hey Michelle — sorry to stick a fork into your Trump Derangement Syndrome — but I, for one, simply voted my mind, my heart, my pocketbook and, yes, my reproductive organs. Despite Democratic hysteria, it's clear to me that the president has no intention of eliminating abortion rights throughout this country. Own opinions There also exist many other issues that concern me. These include runaway crime, the largesse afforded by the previous presidential administration to countless numbers of illegal immigrants, including violent criminals. There's also epic inflation and unchecked antisemitism on college campuses and elsewhere. There's more, but that's a start. In each case, things got so out of hand, I believed Trump had the best chance of saving this nation. Advertisement He couldn't do any worse. I'm no shrinking violet, Michelle. I believe in equal rights — for everyone. And I believe my man is entitled to his own opinions.

CARsgen Presents Research Results on Satri-cel in The Lancet and at the 2025 ASCO Annual Meeting
CARsgen Presents Research Results on Satri-cel in The Lancet and at the 2025 ASCO Annual Meeting

Yahoo

time7 hours ago

  • Yahoo

CARsgen Presents Research Results on Satri-cel in The Lancet and at the 2025 ASCO Annual Meeting

SHANGHAI, June 1, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: a company focused on developing innovative CAR T-cell therapies, announces that the results of the pivotal Phase II clinical trial in China (CT041-ST-01, NCT04581473) investigating satricabtagene autoleucel ("satri-cel", CT041) (a Claudin18.2-specific autologous CAR T-cell product candidate) in patients with Claudin18.2-positive, advanced gastric/gastroesophageal junction cancer refractory to at least two prior lines of treatment, have been published in The Lancet and were orally presented at the 2025 ASCO Annual Meeting. Further details have been posted on the corporate website The article in The Lancet was titled "Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial". Full article available at: The oral presentation at the 2025 ASCO Annual Meeting (Abstract 4003) was titled "Claudin18.2-specific CAR T cells (Satri-cel) versus treatment of physician's choice (TPC) for previously treated advanced gastric or gastroesophageal junction cancer (G/GEJC): Primary results from a randomized, open-label, phase II trial (CT041-ST-01)". Professor Lin Shen from Beijing Cancer Hospital, the principal investigator of this study, said, "The CT041-ST-01 trial represents the world's first randomized controlled clinical study of CAR-T cell therapy for solid tumors. In patients with heavily pretreated, advanced gastric/gastroesophageal junction cancer who have extremely limited treatment options and poor prognosis, satri-cel has demonstrated breakthrough efficacy with significant clinical benefits, including much improved progression-free survival (PFS), overall survival (OS), and tumor response rates. This brings new hope to patients with otherwise medically untreatable conditions. We are further exploring satri-cel's potential in adjuvant settings and as first-line sequential therapies, aiming to intervene earlier in the disease course, extend patients' survival, and ultimately pursue potential cures." Dr. Zonghai Li, Founder, Chairman of the Board, Chief Executive Officer, and Chief Scientific Officer of CARsgen Therapeutics, said, "We are honored that the CT041-ST-01 study results were published in The Lancet—a premier, global medical journal—and presented at the 2025 ASCO Annual Meeting. The positive result of this randomized controlled trial marks a major milestone in solid tumor CAR-T therapy. These achievements are a testament to the whole research team's years of dedication, and we extend our deepest gratitude to patients and their families for their trust and participation. This year, satri-cel has been granted Breakthrough Therapy Designation and Priority Review by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) for the treatment of Claudin18.2-positive advanced gastric/gastroesophageal junction adenocarcinoma (G/GEJA) in patients who have failed at least two prior lines of therapy. We plan to submit a New Drug Application (NDA) for satri-cel to the NMPA this month and anticipate its approval as the world's first commercially available CAR-T product for solid tumors, bringing benefits to patients." About Satri-cel Satri-cel is an autologous CAR T-cell product candidate against the protein Claudin18.2 that has the potential to be the first-in-class globally. Satri-cel targets the treatment of Claudin18.2-positive solid tumors with a primary focus on G/GEJA and pancreatic cancer (PC). Initiated trials include investigator-initiated trials (CT041-CG4006, NCT03874897), a confirmatory Phase II clinical trial for advanced G/GEJA in China (CT041-ST-01, NCT04581473), a Phase Ib clinical trial for PC adjuvant therapy in China (CT041-ST-05, NCT05911217), an investigator-initiated trial for satri-cel be used as consolidation treatment following adjuvant therapy in patients with resected G/GEJA (CT041-CG4010, NCT06857786), and a Phase 1b/2 clinical trial for advanced gastric or pancreatic adenocarcinoma in North America (CT041-ST-02, NCT04404595). Satri-cel has been granted Priority Review by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) for the treatment of Claudin18.2-positive advanced G/GEJA in patients who have failed at least two prior lines of therapy in May 2025. Satri-cel has been granted Breakthrough Therapy Designation by the CDE of China's NMPA for the treatment of Claudin18.2-positive advanced G/GEJA in patients who have failed at least two prior lines of therapy in March 2025. Satri-cel was granted Regenerative Medicine Advanced Therapy designation by U.S. FDA for the treatment of advanced G/GEJA with Claudin18.2-positive tumors in January 2022. Satri-cel received Orphan Drug designation from the U.S. FDA in September 2020 for the treatment of G/GEJA. About CARsgen Therapeutics Holdings Limited CARsgen is a biopharmaceutical company focusing on developing innovative CAR T-cell therapies to address the unmet clinical needs including but not limited to hematologic malignancies, solid tumors and autoimmune diseases. CARsgen has established end-to-end capabilities for CAR T-cell research and development covering target discovery, preclinical research, product clinical development, and commercial-scale production. CARsgen has developed novel in-house technologies and a product pipeline with global rights to address challenges faced by existing CAR T-cell therapies. Efforts include improving safety profile, enhancing the efficacy in treating solid tumors, and reducing treatment costs, etc. CARsgen's mission is to be a global biopharmaceutical leader that provides innovative and differentiated cell therapies for patients worldwide and makes cancer and other diseases curable. Forward-looking Statements All statements in this press release that are not historical fact or that do not relate to present facts or current conditions are forward-looking statements. Such forward-looking statements express the Group's current views, projections, beliefs and expectations with respect to future events as of the date of this press release. Such forward-looking statements are based on a number of assumptions and factors beyond the Group's control. As a result, they are subject to significant risks and uncertainties, and actual events or results may differ materially from these forward-looking statements and the forward-looking events discussed in this press release might not occur. Such risks and uncertainties include, but are not limited to, those detailed under the heading "Principal Risks and Uncertainties" in our most recent annual report and interim report and other announcements and reports made available on our corporate website, No representation or warranty is given as to the achievement or reasonableness of, and no reliance should be placed on, any projections, targets, estimates or forecasts contained in this press release. Contact CARsgen For more information, please visit View original content to download multimedia: SOURCE CARsgen Therapeutics Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store